Navigation Links
Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
Date:1/28/2008

SAN DIEGO, Jan. 28 /PRNewswire/ -- Cylene Pharmaceuticals has appointed Dr. Kenna Anderes to its management team. Dr. Anderes, who brings 17 years of life sciences research experience with a focus on cancer biology research, will serve as Vice President of Cancer Biology. With Cylene's most advanced compound, quarfloxin (CX-3543), now in Phase II development, Dr. Anderes will be leading Cylene's biology and pre-clinical research teams to advance other targeted small molecule oncology compounds into the clinic during 2008.

"I am excited about the opportunity to advance more of Cylene's novel drug candidates into the clinic," said Dr. Anderes. "These compounds are orally available and have the potential to become effective and convenient therapeutics for cancers that currently lack effective, patient-friendly treatments."

Dr. Anderes joined Cylene from Pfizer, Inc., where she had led large project teams in oncology and cancer biology research over the past twelve years. Prior to her tenure at Pfizer, Dr. Anderes held several group leader and senior scientist positions at major biotechnology and pharmaceutical companies, such as Warner Lambert and Agouron.

"Dr. Anderes has the ideal background and experience to accelerate and expand our product pipeline," said Dr. William G. Rice, Cylene's President and Chief Executive Officer. "Her expertise in cancer biomarkers and imaging, as well as her leadership experience in pharmaceutical research, will enable her to make meaningful contributions to our management team."

Dr. Anderes earned a Ph.D. in pharmacology from the Southern Illinois University School of Medicine, and she performed a postdoctoral research fellowship in pharmacology at the University of California San Diego.

About Cylene Pharmaceuticals, Inc.

Cylene Pharmaceuticals is a private company dedicated to the discovery, development and commercialization of targeted small-molecule drugs to treat life-threatening cancers. Using its proprietary Ribosomal RNA Biogenesis Inhibition Technology (RABIT(TM)) to design molecules that combat drug-resistant forms of cancer, Cylene has created multiple product candidates in different stages of development. Cylene's most advanced cancer agent, quarfloxin (CX-3543), is a ribosomal RNA Biogenesis Inhibitor (RBI) in Phase II clinical development in patients having chronic lymphocytic leukemia and in late-stage Phase I development in patients having solid tumors. More information can be found at http://www.cylenepharma.com.


'/>"/>
SOURCE Cylene Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Onyx Pharmaceuticals to Present at Wachovia Healthcare Conference
2. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
3. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
4. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
5. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
6. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
7. QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
8. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
9. Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer
10. Onyx Pharmaceuticals to Present at JPMorgan Healthcare Conference
11. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb. 23, 2017 /PRNewswire/ - The Fight Against Cancer ... Research (OICR) are pleased to report that Fusion Pharmaceuticals ... with Johnson & Johnson Innovation – JJDC, Inc. (JJDC) ... groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, as ... ...
(Date:2/23/2017)... Feb. 23, 2017  Imanis Life Sciences announced ... of oncolytic vaccinia viruses for virotherapy research. These ... of Genelux,s proprietary, vaccinia virus-based technology platform for ... enter into a partnership with Genelux to offer ... viruses for use in research," said Dr. ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... studies (such as insulin, cortisol, CRP, adiponectin, uric acid, and/or other biomarkers or ... Salivary Insulin Assay from Salimetrics’ SalivaLab , the relationship between insulin and ...
(Date:2/23/2017)... SAN FRANCISCO , Feb. 23, 2017 ... company, and Beyond Type 1, a not-for-profit advocacy and ... today announced a grant from Beyond Type 1 to ... type 1 and other insulin-requiring diabetes.  ... innovative stem cell-derived cell replacement therapies with a focus ...
Breaking Biology Technology:
(Date:2/6/2017)... -- According to Acuity Market Intelligence, ongoing concerns ... continue to embrace biometric and digital identification based ... Control (ABC) eGates and 1436 Automated Passport Control ... ports of entry across the globe. Deployments increased ... CAGR of 37%. APC Kiosks reached 75% growth ...
(Date:2/2/2017)...  EyeLock LLC, a market leader of iris-based identity ... What You Should Know About Biometrics in the Cloud ... is a growing concern. In traditional schemes, cryptography is ... authentication schemes such as username/password suffer from inherent weaknesses. ... an elegant solution to the problem of high-security user ...
(Date:1/30/2017)... 2017   Invitae Corporation (NYSE: ... companies, today announced that it will report its fourth ... guidance on Monday, February 13, 2017, and Invitae,s management ... 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... review financial results, guidance, and recent developments and will ...
Breaking Biology News(10 mins):